The Centers for Disease Control and Prevention (CDC) expects it to become the dominant strain during a matter of weeks. Now, there’s one question researchers are racing to answer: Do COVID-19 vaccines boosters Hinders SARS-COV-2 Omicron?
A study from an African country, where Omicron was first detected, found that two doses of Pfizer provided 70% protection against severe COVID-19 and 33% protection against infection during the wave of Omicron infections within the country; folks that previously had COVID-19 had a “significantly higher” likelihood of breakthrough infections.
The research relies on the numerous reports produced by multiple groups using the sets of vaccinated and convalescent serum there. These include sera from individuals infected by wild-type, Alpha, Beta, and Delta variants, using multiple neutralization assays and cell types.
Amidst these revelations, both experts and also the public are now questioning how effective vaccines may be against the variant. But researchers are still awaiting more data on how effective the vaccines and boosters are against Omicron, plus whether it’s more contagious or dangerous than other strains. The CDC recommends that everybody age 5 and above get their first rounds of vaccines, while adults 18 and older roll up their sleeves again for a dose.
The newest variant reported is that the Omicron variant (B.1.1.529) which was first reported on November 24, 2021. It displayed an incredible capacity to spread extensively and rapidly particularly earlier variants. It also resists neutralization by antibodies elicited by the vaccine or by natural infection with earlier variants, including the Delta variant.
With this, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide morbidity, mortality, and social and economic disruptions of the primary order. Despite the rollout of vaccines, the emergence of recent immune escape variants poses a formidable obstacle to ending the pandemic.
Omicron has become dominant in many countries and threatens to cause the following wave of infection. A replacement preprint research paper reports on the state of current knowledge on the immune evasion capability of this variant, linking it to the sort of vaccine used and therefore the vaccination protocol to work out if all vaccines protect against the omicron variant.